History


May 2017

ViraTherapeutics appoints Dr. Heinz Schwer as CEO

ViraTherapeutics announces the appointment of Dr. Heinz Schwer as CEO. He takes over the position from interim CEO and co-founder Prof. Dr. Dorothee von Laer, who will remain a scientific advisor.


May 2017

Grand opening of Christian Doppler Laboratory for Viral Immunotherapy of Cancer at the Medical University of Innsbruck

ViraTherapeutics and Boehringer Ingelheim partner with the Medical University of Innsbruck in the new Christian Doppler Laboratory for cancer viro-immunotherapy. Generous funding is provided by the Christian Doppler Research Association.


September 2016

ViraTherapeutics and Boehringer Ingelheim announce long-term collaboration

ViraTherapeutics and Boehringer Ingelheim announce a new long-term collaboration to develop a next generation oncolytic virus platform and the lead candidate VSV-GP. The potential transaction value is up to EUR 210 million and includes co-funding of development activities and an option to acquire ViraTherapeutics.


August 2016

Closing of Series B financing round

ViraTherpeutics raises 4.1 million Euro in a series B financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF), EMBL Ventures, Empl Privatstiftung and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.


November 2015

ViraTherapeutics inaugurates new laboratory in Innsbruck

ViraTherpeutics inaugurates new facilities in Innsbruck comprising laboratory and office space for its R&D and management staff.


June 2015

Closing of Series A financing round

ViraTherapeutics raises 5.2 million Euro in a series A financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and EMBL Ventures, and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.


December 2014

ViraTherapeutics receives Research Studio Austria grant

The financing was awarded by the Austrian Research Promoting Agency (FFG). In the Research Studio Austria "ViraVet" ViraTherapeutics will collaborate with the verterinary faculties of the universities of Vienna and Munich.


November 2014

ViraTherapeutics receives Seedfinancing grant from aws

The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.


September 2014

ViraTherapeutics as a Business Angel

Empl Privatstiftung invests in ViraTherapeutics as a Business Angel.


July 2013

ViraTherapeutics wins 2nd prize of Science4Life Venture Cup

The second prize of the Science4Life Venture Cup 2013 was awarded to ViraTherapeutics.


June 2013

European patent granted for VSV-GP technology

A patent protecting ViraTherapeutics' proprietary oncolytic virus platform was granted by the European Patent Office. Prior to that, the patent had already been granted in other countries.


April 2013

ViraTherapeutics founded as a GmbH

ViraT was founded as a spin-out of the Medical University of Innsbruck by Prof. Dr. Dorothee von Laer, Head of the Division of Virology at the university, and Dr. Ludwig Weiss. All patents and patent applications for the VSV-GP technology were transferred to ViraTherapeutics.


January 2013

ViraTherapeutics receives preseed grant from aws

The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.


October 2012

ViraTherapeutics wins Best of Biotech

ViraTherapeutics business concept won the first prize of the international Life Science business plan competition "Best of Biotech".


October 2012

ViraTherapeutics wins Tyrolean Innovation Award

ViraTherapeutics' business concept was awarded with the "Innovation Award" of the Tyrolean Chamber of Commerce in the category "Best Concept".


June 2012

ViraTherapeutics wins 1st prize of AdventureX

ViraTherapeutics business concept won the 1st prize of the Tyrolean business plan competition "AdventureX".